CD19 and systemic lupus erythematosus: A recent study demonstrated favorable therapeutic outcomes and controllable safety of anti-CD19 CAR T cells in patients with severe systemic lupus erythematosus, idiopathic inflammatory myositis, and systemic sclerosis [124].